EST. 2021
TechImmune is developing a T-cell–based immunotherapy to address the root cause of Long COVID by clearing persistent SARS-CoV-2 reservoirs and restoring functional anti-viral immunity. Our strategy focuses on conserved non-spike viral antigens that drive protective T cell responses, validated in both human and animal studies. This approach leverages a potential class-defining mechanism of action and the opportunity to deliver the first approved disease-modifying treatment for Long COVID.
With over 40 years’ experience in vaccine science, immunology, and pharmaceutical development. Dr. Young served as the Novavax Board of Directors Chairman from 2011- 3/25. Prior to Novavax, he served as President of Research and Development at MedImmune. He played a key role in the Operation Warp Speed effort while at Novavax.
Dr. Young received his PhD from Baylor College of Medicine and a postdoctoral fellowship at Mt. Sinai School of Medicine in New York.
Mr. Herbert has spent over 50 years in the pharmaceutical industry. He is the co-founder of Allergan Inc., CEO and Chairman of the Board for 30 years. Mr. Herbert served as Executive Vice President of SmithKline Beckman. He received his B.S. in Business, from the University of Southern California.
Dr. Ulmer has >30 years of experience in Vaccines R&D and most recently served as the Global Head of External Research at Novartis and the Head of Preclinical R&D US at GSK Vaccines. Specialties: Biochemistry, Immunology and Cell Biology. Dr. Ulmer received his PhD from McGill University and post-doctoral fellowship at Yale University School of Medicine.
Lbachir BenMohamed, Ph.D.—TechImmune’s vice president, board member, is the key developer and co-inventor of TechImmune’s new, promising T-cell-based immunotherapies for treating chronic Long COVID. A graduate of the Pasteur Institute in Paris, France, he has been a Professor of Immunology at UC Irvine for the last 23 years and the Director of the Laboratory of Cellular and Molecular Immunology at the Gavin S. Herbert Eye Institute. Dr. BenMohamed has over 30 years of experience in vaccines and immunotherapies, a successful record of NIH funding, and a national and international reputation in pre-clinical and clinical development of vaccines and immunotherapies with more than 125 peer-reviewed papers.
Dr. Gil has had a 30+year career in Pharmaceutical R&D as VP of Research at Allergan. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from University of Pennsylvania.
Former Head of Research for Burroughs Welcome, UK for over 20 years. Served as Head of British Pharmaceutical Association. He has been an advisor to the UK Government and G7 pandemic preparedness “100” days initiatives
to develop diagnostics, vaccines, and therapeutics for global use.
Dr. Cavanaugh is the former Managing Director and Senior Advisor to HealthCare Venture LLC, a private equity and venture capital firm specializing in early stage biotechnology investments. He was previously President of SmithKline & French. He also served as President of Allergan International. Dr. Cavanaugh received his B.S. from Farleigh Dickinson University, M.A. and his Ph.D. from University of Iowa.
The former Novavax R&D President has over 30 years of experience in vaccine development, including a fellowship at WRAIR and founding IOMAI for skin-based vaccine delivery, later acquired by Intercell (now Valneva). Joining Novavax in 2010, he specialized in adjuvant and delivery systems for RSV, Influenza, and COVID-19, co-authoring over 140 publications and contributing to the licensure of MatrixM/R21 (Malaria) and Nuvaxovid (COVID-19) vaccines.
Dr. Redfield is the former Director of the Centers for Disease Control and Prevention and a distinguished public health leader with decades of experience in medicine and research. He played a key role as a contributor to Operation Warp Speed, helping accelerate the development of life-saving vaccines during the COVID-19 pandemic. Today, he continues to advance the field through his active involvement in Long COVID clinical research.
At TechImmune, our mission is to deliver a class-defining immunotherapy that addresses the urgent global challenge of Long COVID. By leveraging a novel mechanism of T-cell antigen stimulation, we aim to restore immune balance, clear persistent viral reservoirs, and provide lasting relief for patients. We are committed to transforming the lives of millions living with Long COVID while reducing the growing burden this condition places on healthcare systems worldwide.